Avidity Biosciences, Inc. announced on January 4, 2022, Joseph Baroldi informed the company of his intention to resign as Chief Operating Officer of the Company to pursue a new opportunity. His last day at the Company will be January 21, 2022. The Company has entered into a post-employment consulting agreement with Mr. Baroldi for a term of six months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.64 USD | -0.80% | +49.02% | +338.01% |
Jun. 14 | Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating | MT |
Jun. 14 | Avidity Biosciences Prices $400.9 Million Offering of Shares | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+338.01% | 4.21B | |
+0.85% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Announces Resignation of Joseph Baroldi as Chief Operating Officer, Effective January 22, 2022